CH \$640.00

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NHS BLOOD AND TRANSPLANT (TRADING AS BIO PRODUCTS LABORATORY)	12/20/2010

RECEIVING PARTY DATA

Name:	BIO PRODUCTS LABORATORY LIMITED	
Street Address:	DAGGER LANE	
Internal Address:	ELSTREE	
City:	HERTFORDSHIRE	
State/Country:	UNITED KINGDOM	
Postal Code:	WD6 3BX	

PROPERTY NUMBERS Total: 16

Property Type	Number
Patent Number:	7816495
Patent Number:	5831063
Patent Number:	5487981
Patent Number:	5496548
Patent Number:	5304638
Patent Number:	5445958
Patent Number:	6387877
Patent Number:	5907032
Patent Number:	5831027
Patent Number:	7252720
Application Number:	10520457
Application Number:	12886290
Application Number:	11577478
Application Number:	12095488
	DATENT

PATENT " REEL: 026177 FRAME: 0596

501511034

Application Number:	12601930
Application Number:	09889645

CORRESPONDENCE DATA

Fax Number: (949)760-9502

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 949-760-0404

Email: EFILING@KMOB.COM

Correspondent Name: KNOBBE MARTENS OLSON & BEAR LLP

Address Line 1: 2040 MAIN STREET

Address Line 2: 14TH FLOOR

Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER: DHEN7.000GEN

NAME OF SUBMITTER: Raymond D. Smith (Reg. No. 55,634)

Total Attachments: 10

source=DEHN7ASSIGNMENTNHSTOBIO#page1.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page2.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page3.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page4.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page5.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page6.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page7.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page8.tif


source=DEHN7ASSIGNMENTNHSTOBIO#page9.tif

source=DEHN7ASSIGNMENTNHSTOBIO#page10.tif




- (1) NHS BLOOD AND TRANSPLANT (trading as BIO PRODUCTS LABORATORY)
 - (2) BIO PRODUCTS LABORATORY LIMITED

PATENT ASSIGNMENT







2010

BETWEEN:

- NHS BLOOD AND TRANSPLANT (TRADING AS BIO PRODUCTS LABORATORY), (1) a Special Health Authority in succession to the National Blood Authority of England established by United Kingdom Statutory Instruments (numbers 2529, 2531, 2532 of 2005) of Dagger Lane, Elstree, Hertfordshire WD6 3BX ("Assignor"); and
- (2)BIO PRODUCTS LABORATORY LIMITED, a Private Limited Company (number 7343036) registered at Companies House under section 1115 of the Companies Act 2006 and having its principal office at Dagger Lane, Elstree, Hertfordshire WD6 3BX ("Assignee").

WHEREAS:

- The Assignor is the proprietor of the patents and the patent applications set out in (A) Schedule 1 hereto (the "Patents").
- Pursuant to a Business Transfer Agreement entered into by the parties on the same (B) date as this Assignment (the "Agreement"), the Assignor has agreed to assign the Patents to the Assignee on the terms set out in this Assignment and subject to the terms set out in the Agreement.

IT IS AGREED as follows:

ASSIGNMENT 1.

In consideration of the Assignee entering into the Agreement and the consideration of the payment of £1 by the Assignee to the Assignor (the receipt and sufficiency of which the Assignor hereby confirms) the Assignor hereby assigns to the Assignee with full title guarantee:

- all of its rights, title and interest in and to the Patents; and 1.1
- 1.2 all rights and powers arising or accrued therefrom (whether under statute or common law) including the right to sue for damages and other remedies in respect of any prior infringement of the Assignor's rights in or in respect of the Patents and to retain any and all sums obtained through such actions and the right to apply for, prosecute and obtain patent or similar protection throughout the world in respect of the inventions therein including any rights to claim priority therefrom to the intent that the grant of any patent or similar protection shall be in the name of and vest in the Assignee.

FURTHER ASSURANCE 2.

2.1 The Assignor further covenants that at the request and cost of the Assignee it will at all times:

1

- 2.1.1 do all such reasonable acts and execute all such documents as may be reasonably necessary or desirable to secure the vesting in the Assignee of all rights assigned to it under this Assignment; and
- 2.1.2 use reasonable endeavours to assist in the resolution of any question arising from the prosecution of any patent applications set out in Schedule 1.

20\23693529.2\LJF

3. CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999

A person who is not a party to this Assignment shall have no rights under the Contracts (Rights of Third Parties) Act 1999 to rely upon or enforce any term of this Assignment provided that this does not affect any right or remedy of the third party which exists or is available apart from that Act. No party may declare itself as a trustee of the rights under this Assignment for the benefit of any third party save as expressly provided in this Assignment.

4. LAW AND JURISDICTION

- 4.1 This Assignment shall be governed by and construed in accordance with the laws of England.
- 4.2 The parties hereby submit to the exclusive jurisdiction of the courts of England in relation to any dispute or claim arising out of, or in connection with, this Assignment.

This Assignment has been executed by authorised representatives of the Assignor and Assignee on the date stated at the beginning of it

SCHEDULE 1

The Patents

Patents

Group	Indicative subject matter	Patent Number	Country
1	Thrombin	2003244858	Australia
1	Thrombin	262404	Mexico
1	Thrombin	1520018	UK
1	Thrombin	1520018	Austria
1	Thrombin	1520018	Belgium
1	Thrombin	1520018	Cyprus
1	Thrombin	1520018	France
1	Thrombin	1520018/60311990.5	Germany
1	Thrombin	1520018	Hungary
1	Thrombin	1520018	Italy
1	Thrombin	1520018	Netherlands
1	Thrombin	1520018	Portugal
1	Thrombin	1520018	Spain
1	Thrombin	1520018	Sweden
	Thrombin	1520018	Switzerland
1	Thrombin	4445386	Japan
2	Fibrinogen	2003244850	Australia
2	Fibrinogen	1519944	Austria
2	Fibrinogen	1519944	Belgium
2	Fibrinogen	1519944	Switzerland
2	Fibrinogen	1519944/60330146.0- 08	Germany
2	Fibrinogen	1519944	Denmark
2	Fibrinogen	1519944	Spain
2	Fibrinogen	1519944	France

2	Fibrinogen	1519944	UK
2	Fibrinogen	1519944	Italy
2	Fibrinogen	1519944	Netherlands
2	Fibrinogen	1519944	Sweden
2	Fibrinogen	4324102	Japan
2	Fibrinogen	270428	Mexico
2	Fibrinogen	7816495	USA
4	Human monoclonal anti-D	5831063	USA
4	Human monoclonal anti-D	5919910	USA
5	Anti-Rh(D) Mabs (Kumpel 1)	5487891	USA
5	Anti-Rh(D) Mabs (Kumpel 1)	5665356	USA
6	Anti-Rh(D) Mabs (Kumpel 2)	5496548	USA
6	Anti-Rh(D) Mabs (Kumpel 2)	5653978	USA
7	Teta Sepharose	5304638	USA
8	Metal chelate chromatography	5445958	USA
10	AAG	6387877	USA
10	AAG	6992061	USA
10	AAG	3713277	Japan
12	Thrombin	709673	Australia
12	Thrombin	813598	Austria
12	Thrombin	813598	Switzerland
12	Thrombin	813598	France
12	Thrombin	813598	UK
12	Thrombin	813598	[reland
12	Thrombin	813598	Italy
12	Thrombin	813598	Netherlands

12	Thrombin	813598	Germany
12	Thrombin	813598	Spain
12	Thrombin	5907032	USA
12	Thrombin	3819935	Japan
13	Fibrinogen	692018	Australia
13	Fibrinogen	804254	Austria
13	Fibrinogen	804254	Belgium
13	Fibrinogen	804254	Switzerland
13	Fibrinogen	804254	Denmark
13	Fibrinogen	804254	France
13	Fibrinogen	804254	UK
13	Fibrinogen	804254	Italy
13	Fibrinogen	2206670	Canada
13	Fibrinogen	804254	Germany
13	Fibrinogen	804254	Spain
13	Fibrinogen	804254	Sweden
13	Fibrinogen	4181214	Japan
13	Fibrinogen	5831027	USA
14	Treating Protein liquids	774996	Australia
14	Treating Protein liquids	2359932	Canada
14	Treating Protein liquids	1144015	Austria
14	Treating Protein liquids	1144015	Belgium
14	Treating Protein liquids	1144015	Switzerland
14	Treating Protein liquids	1144015	Denmark
14	Treating Protein liquids	1144015	Finland
14	Treating Protein liquids	1144015	France
14	Treating Protein liquids	1144015	UK
14	Treating Protein liquids	1144015	Greece
14	Treating Protein liquids	1144015	Ireland

14	Treating Protein liquids	1144015	Italy
14	Treating Protein liquids	1144015	Netherlands
14	Treating Protein liquids	1144015	Portugal
14	Treating Protein liquids	1144015	Spain
14	Treating Protein liquids	1144015	Sweden
14	Treating Protein liquids	1144015	Germany
14	Treating Protein liquids	4524045	Japan
15	Removal of Prion Infectivity	1534348	Austria
15	Removal of Prion Infectivity	1534348	Germany
15	Removal of Prion Infectivity	1534348	Spain
15	Removal of Prion Infectivity	1534348	France
15	Removal of Prion Infectivity	1534348	UK
15	Removal of Prion Infectivity	1534348	Italy
15	Removal of Prion Infectivity	1534348	Netherlands
15	Removal of Prion Infectivity	2003242838	Australia
15	Removal of Prion Infectivity	7252720	USA

Patent Applications

Group	Indicative subject matter	Patent Application Number	Country	PCT filing Date
1	Thrombin	PI0312522-0	Brazil	07-Jul-2003
1	Thrombin	2491718	Canada	07-Jul-2003
1	Thrombin	165989	Israel	07-Jul-2003
1	Thrombin	10/520457	USA	07-Jul-2003
1	Thrombin	P-374747	Poland	07-Jul-2003
1	Thrombin	201146	Israel	07-Jul-2003

2	Fibrinogen	PI0312521-1	Brazil	07-Jul-2003
2	Fibrinogen	2491716	Canada	07-Jul-2003
2	Fibrinogen	165988	Israel	07-Jul-2003
2	Fibrinogen	P-374080	Poland	07-Jul-2003
3	Haptoglobin	12/886290	USA	30-Apr-2008
3	Haptoglobin	2005297061	Australia	19-Oct-2005
3	Haptoglobin	2007-537377	Japan	19-Oct-2005
3	Haptoglobin	2007004244	Mexico	19-Oct-2005
3	Haptoglobin	11/577478	USA	19-Oct-2005
3	Haptoglobin	386/2007	Egypt	19-Oct-2005
3	Haptoglobin	P10516933	Brazil	19-Oct-2005
3	Haptoglobin	2584407	Canada	19-Oct-2005
3	Haptoglobin	182340	Israel	19-Oct-2005
3	Haptoglobin	1802654	Europe	19-Oct-2005
9	Alpha-1- antitrypsin	PI0619230-0	Brazil	29-Nov-2006
9	Alpha-1- antitrypsin	CA2631524	Canada	29-Nov-2006
9	Alpha-1- antitrypsin	AU2006321447	Australia	29-Nov-2006
9	Alpha-1- antitrypsin	12/095488	USA	29-Nov-2006
9	Alpha-1- antitrypsin	1973563	Europe	29-Nov-2006
11	Factor X	2152867	Europe	29-May- 2008
11	Factor X	2009/07631	South Africa	29-May- 2008
11	Factor X	12/601930	USA	29-May- 2008
11	Factor X	2010-509888	Japan	29-May- 2008
11	Factor X	2008257222	Australia	29-May- 2008

11	Factor X	2687604	Canada	29-May- 2008
11	Factor X	201931	Israel	29-May- 2008
12	Thrombin	2212832	Canada	23-Feb-1996
14	Treating Protein liquids	09/889645	USA	19-Jan-2000
15	Removal of Prion Infectivity	2488502	Canada	30-May- 2003

Signed for and on behalf of NHS BLOOD AND TRANSPLANT (trading as BIO PRODUCTS LABORATORY) by:	Jalau Su- Name
	Chief Executive
	23.12.13
	Date
Signed for and on behalf of BIO PRODUCTS LABORATORY LIMITED by:	Name Orreder Title Z3. 12. 10 Date

20\23693529.2\LJF

RECORDED: 04/25/2011